Patara Pharma

New biotech ThirtyFiveBio has emerged from stealth mode following a $20m seed financing as it advances a first-in-class G Protein-Coupled Receptor 35 (GPR35) antagonist approach for the treatment of

In a summer slowdown, biopharmaceutical start-up fundraising declined 27% in the third quarter of 2018, but Gossamer Bio Inc. and Orchard Therapeutics Ltd. brought in large venture capital rounds

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Roivant Sciences GMBH is launching its 13th subsidiary, or "vant," this time focused on the development of respiratory diseases. The new Respivant will focus initially on the development of a Phase